Protective role of autophagy and autophagy-related protein 5 in early tumorigenesis
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 60554395X | ||
| 003 | CHVBK | ||
| 005 | 20210128100929.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150201xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s00109-014-1241-3 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s00109-014-1241-3 | ||
| 245 | 0 | 0 | |a Protective role of autophagy and autophagy-related protein 5 in early tumorigenesis |h [Elektronische Daten] |c [He Liu, Zhaoyue He, Hans-Uwe Simon] |
| 520 | 3 | |a Autophagy, a fundamental cellular catabolic process, is involved in the development of numerous diseases including cancer. Autophagy seems to have an ambivalent impact on tumor development. While increasing evidence indicates a cytoprotective role for autophagy that can contribute to resistance against chemotherapy and even against the adverse, hypoxic environment of established tumors, relatively few publications focus on the role of autophagy in early tumorigenesis. However, the consensus is that autophagy is inhibitory for the genesis of tumors. To understand this apparent contradiction, more detailed information about the roles of the individual participants in autophagy is needed. This review will address this topic with respect to autophagy-related protein 5 (ATG5), which in several lines of investigation has been ascribed special significance in the autophagic pathway. Furthermore, it was recently shown that an ATG5 deficiency in melanocytes interferes with oncogene-induced senescence, thus promoting melanoma tumorigenesis. Similarly, an ATG5 deficiency resulted in tumors of the lung and liver in experimental mouse models. Taken together, these findings indicate that ATG5 and the autophagy to which it contributes are essential gatekeepers restricting early tumorigenesis in multiple tissues. | |
| 540 | |a Springer-Verlag Berlin Heidelberg, 2014 | ||
| 690 | 7 | |a Adenoma |2 nationallicence | |
| 690 | 7 | |a Autophagy |2 nationallicence | |
| 690 | 7 | |a ATG5 |2 nationallicence | |
| 690 | 7 | |a Melanoma |2 nationallicence | |
| 690 | 7 | |a Oncogenesis |2 nationallicence | |
| 690 | 7 | |a Senescence |2 nationallicence | |
| 690 | 7 | |a Tumorigenesis |2 nationallicence | |
| 700 | 1 | |a Liu |D He |u Institute of Pharmacology, University of Bern, Friedbuehlstrasse 49, 3010, Bern, Switzerland |4 aut | |
| 700 | 1 | |a He |D Zhaoyue |u Institute of Pharmacology, University of Bern, Friedbuehlstrasse 49, 3010, Bern, Switzerland |4 aut | |
| 700 | 1 | |a Simon |D Hans-Uwe |u Institute of Pharmacology, University of Bern, Friedbuehlstrasse 49, 3010, Bern, Switzerland |4 aut | |
| 773 | 0 | |t Journal of Molecular Medicine |d Springer Berlin Heidelberg |g 93/2(2015-02-01), 159-164 |x 0946-2716 |q 93:2<159 |1 2015 |2 93 |o 109 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00109-014-1241-3 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a review-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s00109-014-1241-3 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Liu |D He |u Institute of Pharmacology, University of Bern, Friedbuehlstrasse 49, 3010, Bern, Switzerland |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a He |D Zhaoyue |u Institute of Pharmacology, University of Bern, Friedbuehlstrasse 49, 3010, Bern, Switzerland |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Simon |D Hans-Uwe |u Institute of Pharmacology, University of Bern, Friedbuehlstrasse 49, 3010, Bern, Switzerland |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Journal of Molecular Medicine |d Springer Berlin Heidelberg |g 93/2(2015-02-01), 159-164 |x 0946-2716 |q 93:2<159 |1 2015 |2 93 |o 109 | ||